توصلت دراسة صغيرة إلى أن علاج خلايا CAR-T قد يوفر طريقة جديدة للسيطرة على فيروس نقص المناعة البشرية على المدى الطويل. ويتضمن هذا النهج، المستخدم بالفعل في علاج أنواع معينة من السرطان، تعديل الخلايا المناعية الخاصة بالمريض.
يعيد الباحثون استخدام هذا العلاج لفيروس نقص المناعة البشرية بعد ملاحظة مؤشرات أولية إيجابية لدى شخصين. ويبدو أن الخلايا المعدلة تساعد في السيطرة على الفيروس دون الحاجة إلى تدخل مستمر.
من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي
A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.
A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.
من إعداد الذكاء الاصطناعي
Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.
An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.
من إعداد الذكاء الاصطناعي
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.